Our top pick for
Sage Therapeutics, Inc is a biotechnology business based in the US. Sage Therapeutics shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutics employs 675 staff and has a trailing 12-month revenue of around USD$8.9 million.
Since the stock market crash in March caused by coronavirus, Sage Therapeutics's share price has had significant positive movement.
Its last market close was USD$73.47, which is 5.36% up on its pre-crash value of USD$69.53 and 193.76% up on the lowest point reached during the March crash when the shares fell as low as USD$25.01.
If you had bought USD$1,000 worth of Sage Therapeutics shares at the start of February 2020, those shares would have been worth USD$388.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,090.29.
|Latest market close||USD$73.47|
|52-week range||USD$25.01 - USD$155.33|
|50-day moving average||USD$59.64|
|200-day moving average||USD$45.7324|
|Wall St. target price||USD$79.05|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-12.679|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-15)||N/A|
|1 month (2020-10-26)||7.26%|
|3 months (2020-08-22)||N/A|
|6 months (2020-05-22)||88.67%|
|1 year (2019-11-22)||-50.69%|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||-23.02%|
|5 years (2015-11-22)||N/A|
Valuing Sage Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sage Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$8.9 million|
|Gross profit TTM||USD$-362,347,000|
|Return on assets TTM||-35.24%|
|Return on equity TTM||-62.97%|
|Market capitalisation||USD$3.6 billion|
TTM: trailing 12 months
There are currently 6.2 million Sage Therapeutics shares held short by investors – that's known as Sage Therapeutics's "short interest". This figure is 14.5% down from 7.3 million last month.
There are a few different ways that this level of interest in shorting Sage Therapeutics shares can be evaluated.
Sage Therapeutics's "short interest ratio" (SIR) is the quantity of Sage Therapeutics shares currently shorted divided by the average quantity of Sage Therapeutics shares traded daily (recently around 721251.80023229). Sage Therapeutics's SIR currently stands at 8.61. In other words for every 100,000 Sage Therapeutics shares traded daily on the market, roughly 8610 shares are currently held short.
However Sage Therapeutics's short interest can also be evaluated against the total number of Sage Therapeutics shares, or, against the total number of tradable Sage Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sage Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Sage Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1651% of the tradable shares (for every 100,000 tradable Sage Therapeutics shares, roughly 165 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sage Therapeutics.
Find out more about how you can short Sage Therapeutics stock.
We're not expecting Sage Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Sage Therapeutics's shares have ranged in value from as little as $25.01 up to $155.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutics's is 2.455. This would suggest that Sage Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.